Clinical Trials
Last Updated: 2/8/2011
Untreated
Indolent Lymphoma
Intermediate/High Grade Lymphoma
Hodgkin's Lymphoma
- ABVD (2007-0144)
- ABVD, Brentuximab Vedotin (2009-0801)
- Interim PET response adapted therapy (SWOG SO816)
Mantle Cell Lymphoma
- Bortezomib + R-HyperCVAD alternating with Bortezomib+ R-High dose Methotrexate/Cytarabine (2006-0697)
Peripheral T-Cell Lymphoma
Multiple Myeloma/Waldenstrom’s
- Bortezomib, CNTO328, Melphalan, Prednisone (2009-0113)
- Bortezomib, Lenalidomide, Dexamethasone, Vorinostat (2008-0794)
- Bortezomib, Lenalidomide, Dexamethasone (SWOG SO0777)
Prior Treatment
Indolent Lymphoma
- Milatuzumab (2008-0075)
- CT-011, Rituximab (2009-0163)
- MK-2206 (2010-0261)
- Bendamustine, GA101 (2010-0197)
- Panobinostat, Everloimus (2008-0805)
- HCD 122 (2008-0062)
- CNTO 328 (2009-0608)
- MGCD0103 (2006-0417)
- SB1518 (2010-0492)
Intermediate Grade Lymphoma
- CC-5013 + Rituxan (2005-0461)
- Milatuzumab (2008-0075)
- Ofatumumab, ICE/DHAP (2008-0841)
- MK-2206 (2010-0261)
- Panobinostat, Everolimus (2008-0805)
Hodgkin's Lymphoma
- HCD 122 (2008-0062)
- Bortezomib, ICE (2008-0604)
- Panobinostat, ICE (2010-0065)
- Brentuximab, vedotin (2010-0453)
- Entinostat (2008-0769)
- MK-2206 (2010-0261)
- Panobinostat, Everolimus (2008-0805)
- RAD001 (2010-0228)
- SB1518 (2010-0492)
- SGN-35 (2009-0130)
- PLX3397 (2010-0649)
Mantle Cell Lymphoma
- Bortezomib, Cyclosphosphamide, Rituximab (2009-0057)
- RAD001 (2008-0436)
- Panobinostat, Everolimus (2008-0805)
- MK-2206 (2010-0261)
- PCI-32765 (2008-0494)
- MLN4924 (2008-0135)
- SB1518 (2010-0492)
Peripheral T-cell Lymphoma
Multiple Myeloma/Waldenstrom's
- Lenalidomide, Dexamethasone, Panobinostat (2010-0323)
- Lenalidomide, Dexamethasone, Panobinostat (2010-0398)
- ARRY-520 (2008-0500)
- Dexamethesone, Lenalidomide, Thalidomide (2009-0179)
- MLN9708 (2009-0355)
- Bortezomib, KW2478 (2009-0902)
- Carfilzomib maintenance (2010-0029)
Phase I Agents